CD63 and Alzheimer disease: To verify and further characterize the GFAPlowAQP4+CD63+ subpopulation in vivo, we performed immunohistochemistry (IHC) using antibodies against GFAP, CD63, and AQP4 in control and AD samples (Fig. 4D and E).